Literature DB >> 11448661

Treatment of chronic headache with antidepressants: a meta-analysis.

G E Tomkins1, J L Jackson, P G O'Malley, E Balden, J E Santoro.   

Abstract

BACKGROUND: Although antidepressants are often used for preventing chronic headache, their effectiveness is uncertain.
METHODS: We performed a meta-analysis of English-language, randomized placebo-controlled trials of antidepressants as prophylaxis for chronic headache.
RESULTS: Thirty-eight trials were included. Because some compared more than one drug with placebo, 44 study arms were combined using a random effects model. Twenty-five studies focused on migraines, 12 on tension headaches, and 1 on both. Nineteen used tricyclic antidepressants, 18 serotonin antagonists, and 7 selective serotonin reuptake inhibitors. Patients receiving antidepressants were twice as likely to report headache improvement (rate ratio [RR]: 2.0; 95% confidence interval [CI]: 1.6 to 2.4). Because 31% (95% CI: 23% to 40%) more treated patients improved than those receiving placebo, clinicians would need to treat 3.2 patients for 1 patient to improve. The average amount of improvement (standardized mean difference) was 0.94 (95% CI: 0.65 to 1.2), an effect considered large. Treated patients also consumed less analgesic medication (standardized mean difference, -0.7; 95% CI: -0.5 to -0.94). There were no differences in outcomes among the three classes of agents studied or by the type of headache (migraine vs. tension), quality score, length of treatment, or percentage of patients lost to follow-up. Assessment of depression across studies was insufficient to determine if the effects were independent of depression.
CONCLUSION: Antidepressants are effective in preventing chronic headaches. Whether this is independent of depression and whether there are differences in efficacy by class of agent needs further study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448661     DOI: 10.1016/s0002-9343(01)00762-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

Review 1.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

Review 2.  Acute and prophylactic treatments for migraine: present and future.

Authors:  Alan M Rapoport
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

3.  Paroxetine alleviates rat limb post-ischemia induced allodynia through GRK2 upregulation in superior cervical ganglia.

Authors:  Jun Tang; Jing Dong; Li Yang; Lingqi Gao; Jijian Zheng
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management.

Authors:  Kurt Kroenke
Journal:  Int J Methods Psychiatr Res       Date:  2003       Impact factor: 4.035

Review 5.  Serotonin and migraine: a reconsideration of the central theory.

Authors:  Alessandro Panconesi
Journal:  J Headache Pain       Date:  2008-07-31       Impact factor: 7.277

Review 6.  [A chronic problem-the chronic headache patient].

Authors:  A Straube
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

Review 7.  Pharmacotherapy of tension-type headaches.

Authors:  Mark J Stillman
Journal:  Curr Pain Headache Rep       Date:  2002-10

Review 8.  Tricyclic antidepressants and headaches: systematic review and meta-analysis.

Authors:  Jeffrey L Jackson; William Shimeall; Laura Sessums; Kent J Dezee; Dorothy Becher; Margretta Diemer; Elizabeth Berbano; Patrick G O'Malley
Journal:  BMJ       Date:  2010-10-20

Review 9.  Antidepressants for the treatment of chronic pain.

Authors:  Bénédicte Verdu; Isabelle Decosterd; Thierry Buclin; Friedrich Stiefel; Alexandre Berney
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.